NCT05636267 2026-03-09
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
Akeso
Phase 1/2 Terminated
Clinical Trials
10 trialsNCT04820023 2025-06-06
Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment
Bridge Biotherapeutics, Inc.
Phase 1/2 Terminated
NCT06940401 2025-05-14
JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations
Suzhou Junjing BioSciences Co., Ltd.
Phase 1/2 Recruiting
NCT05994131 2025-04-30
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT05383898 2024-10-15
Study to Evaluate D-1553 in Subjects With Lung Cancer
InventisBio Co., Ltd
Phase 1/2 Completed
NCT05492045 2024-10-15
A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer
InventisBio Co., Ltd
Phase 1/2 Terminated
NCT04402008 2024-06-25
Study of Poziotinib in Japanese Patients With NSCLC
Spectrum Pharmaceuticals, Inc
Phase 1/2 Terminated
NCT05332574 2022-08-05
A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor
Genor Biopharma Co., Ltd.
Phase 1/2 Unknown
NCT03562871 2022-04-21
IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC
IO Biotech
Phase 1/2 Completed
NCT00072618 2011-10-20
Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients
Astellas Pharma Inc
Phase 1/2 Completed